Hepatic Impaired Subjects Compared to Healthy Subjects Receiving Multi-dose BMS-650032
NCT01019070 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 28
Last updated 2011-10-26
Summary
The purpose of this study is to assess the effects of hepatic impairment on the multiple dose pharmacokinetics of BMS-650032.
Conditions
- Hepatic Insufficiency
Interventions
- DRUG
-
BMS-650032
Capsules, Oral, 200 mg, BID, 7 Days
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Bristol-Myers Squibb · Bristol-Myers Squibb
Study Design
- Allocation
- NON_RANDOMIZED
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2009-12-31
- Primary Completion
- 2011-08-31
- Completion
- 2011-08-31
Countries
- United States
Study Locations
More Related Trials
-
A Study to Evaluate the Drug Levels, Safety, and Tolerability of BMS-986036 in Participants With Normal Liver Function and Participants With Moderate and Severe Liver Impairment
NCT04634149 ·Status: COMPLETED ·Phase: PHASE1
-
An Investigational Study of BMS-986165 in Participants With Normal Liver Function and Participants With Mild to Severe Liver Damage
NCT03890809 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Assess the Drug Levels of Repotrectinib in Healthy Participants and Participants With Moderate and Severe Hepatic Impairment
NCT06352528 ·Status: COMPLETED ·Phase: PHASE1
-
Absorption, Distribution, Metabolism and Excretion (ADME) Study of BMS-986020
NCT02068053 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Mezigdomide in Healthy Participants and Participants With Hepatic Impairment
NCT05707390 ·Status: COMPLETED ·Phase: PHASE1
-
An Investigational Study of Experimental Medication BMS-986231 Given in Participants With Different Levels of Liver Function
NCT03515980 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Assess the Drug Levels and Safety of BMS-986435 in Participants With Normal Hepatic Function and Participants With Different Degrees of Hepatic Impairment
NCT07248839 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
A Pharmacokinetic Study of MK-3102 in Participants With Impaired Hepatic Function (MK-3102-031)
NCT01767688 ·Status: COMPLETED ·Phase: PHASE1
-
Single-dose Pharmacokinetics of BMS-626529, Administered as BMS-663068, in Subjects With Hepatic Impairment Compared to Healthy Subjects
NCT02467335 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate Pharmacokinetics (PK) and Safety of Oral Mobocertinib in Participants With Moderate or Severe Hepatic Impairment (HI) and Normal Hepatic Function
NCT04056468 ·Status: COMPLETED ·Phase: PHASE1
-
Effect Of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of PF-06865571 In Subjects With Hepatic Impairment and in Healthy Subjects
NCT04091061 ·Status: COMPLETED ·Phase: PHASE1
-
Open Label Pharmacokinetic Study of SAR302503 in Subjects With Hepatic Impairment
NCT01762462 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Drug Levels of BMS-986165 When Taken as Various Solid Tablet Prototypes by Healthy Participants
NCT04536961 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Effect of IV Doses of Rivipansel in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function
NCT02871570 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetics and Metabolism of [14C] BMS-986231 in Healthy Male Participants
NCT03210909 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Dasatinib to See How Liver Impaired and Healthy Subjects Process and React to the Study Drug
NCT00382668 ·Status: COMPLETED
-
An Investigational Study of ESK-001 in Participants With Normal Liver Function and Participants With Mild, Moderate, and Severe Liver Damage
NCT06952634 ·Status: COMPLETED ·Phase: PHASE1
-
Single-Dose, Open-Label Pharmacokinetic Study of Bardoxolone Methyl in Subjects With Mild, Moderate, and Severe Hepatic Impairment and Normal Hepatic Function
NCT01563562 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Investigate the Effect of Mild and Moderate Hepatic Impairment on the Safety and Tolerability of Fezolinetant Compared to Participants With Normal Hepatic Function
NCT04482270 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Assess Drug Levels and Safety of Golcadomide (BMS-986369) in Healthy Participants and Participants With Different Degrees of Hepatic Impairment
NCT06535399 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetics (Drug Levels in Blood) of BMS-986165 When Taken as Various Solid Tablet Prototypes by Healthy Participants
NCT04249284 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Drug Levels, Physical and Chemical Changes, and Removal of BMS-986196 in Healthy Male Participants
NCT05981963 ·Status: COMPLETED ·Phase: PHASE1
-
An Investigational Study to Determine the Drug Level Profile of BMS-986165 in Healthy Male Volunteers Following Transporter Inhibition.
NCT04086719 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Pharmacokinetics (Drug Levels and Metabolism), Safety, and Tolerability of BMS-986259 in Participants With Various Levels of Kidney Function
NCT04237831 ·Status: COMPLETED ·Phase: PHASE1
-
A Pharmacokinetic Study of Simufilam in Subjects With Impaired Hepatic Function
NCT06390410 ·Status: COMPLETED ·Phase: PHASE1